Related Experiment Video
Updated: Jul 29, 2025
Monitoring of Nanodrug Accumulation in Murine Breast Cancer Metastases
Published on: August 23, 2024
The DNMT3B Inhibitor Nanaomycin A as a Neuroblastoma Therapeutic Agent
Kazuya Izumi1, Hiromasa Aoki1, Hiroki Kakita1,2
1Department of Pathobiology, Nagoya City University Graduate School of Pharmaceutical Sciences, 3-1 Tanabe-dori, Mizuho-ku, Nagoya, Aichi, 467-8603, Japan.
Background:
Neuroblastoma is one of the most common childhood solid tumors. Because tumor suppressor genes are often hypermethylated in cancers, DNA methylation has emerged as a target for cancer therapeutics. Nanaomycin A, an inhibitor of DNA methyltransferase 3B, which mediates de novo DNA methylation, reportedly induces death in several types of human cancer cells.
Objective:
To study the antitumor activity of nanaomycin A against neuroblastoma cell lines and its mechanism.
Methods:
The anti-tumor effect of nanaomycin A on neuroblastoma cell lines was evaluated based on cell viability, DNA methylation levels, apoptosis-related protein expression, and neuronal-associated mRNA expression.
Results:
Nanaomycin A decreased genomic DNA methylation levels and induced apoptosis in human neuroblastoma cells. Nanaomycin A also upregulated the expression of mRNAs for several genes related to neuronal maturation.
Conclusions:
Nanaomycin A is an effective therapeutic candidate for treating neuroblastoma. Our findings also suggest that the inhibition of DNA methylation is a promising anti-tumor therapy strategy for neuroblastoma.
Insights
Nanaomycin A shows promise as a neuroblastoma treatment by reducing DNA methylation and inducing cancer cell death. This study highlights DNA methylation inhibition as a potential therapeutic strategy for childhood neuroblastoma.
Area of Science:
- Oncology
- Cancer Therapeutics
- Epigenetics
Background:
- Neuroblastoma is a frequent childhood solid tumor.
- DNA methylation is a key epigenetic mechanism implicated in cancer development.
- Nanaomycin A, a DNA methyltransferase 3B inhibitor, demonstrates anti-cancer properties.
Purpose of the Study:
- To investigate the antitumor effects of Nanaomycin A on neuroblastoma cell lines.
- To elucidate the mechanism of Nanaomycin A's action in neuroblastoma.
Main Methods:
- Assessing cell viability and DNA methylation levels.
- Analyzing apoptosis-related protein expression.
- Measuring neuronal-associated mRNA expression.
Main Results:
- Nanaomycin A significantly reduced genomic DNA methylation in neuroblastoma cells.
- Induced apoptosis was observed in human neuroblastoma cells treated with Nanaomycin A.
- Upregulation of neuronal maturation-associated gene expression was noted.
Conclusions:
- Nanaomycin A presents a viable therapeutic candidate for neuroblastoma treatment.
- Inhibiting DNA methylation is a promising strategy for anti-neuroblastoma therapy.
More Related Videos
Related Concept Videos
01:28Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists
01:26Directly Acting Muscle Relaxants: Dantrolene and Botulinum Toxin
The binding of dantrolene to the RYR1...